IL311784A - Substituted sulfonylurea compounds as inhibitors of interleukin-1 activity - Google Patents
Substituted sulfonylurea compounds as inhibitors of interleukin-1 activityInfo
- Publication number
- IL311784A IL311784A IL311784A IL31178424A IL311784A IL 311784 A IL311784 A IL 311784A IL 311784 A IL311784 A IL 311784A IL 31178424 A IL31178424 A IL 31178424A IL 311784 A IL311784 A IL 311784A
- Authority
- IL
- Israel
- Prior art keywords
- inlerleukin
- sulfonylureas
- inhibitors
- activity
- converted
- Prior art date
Links
- 229940100389 Sulfonylurea Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021121548 | 2021-09-29 | ||
| PCT/US2022/077120 WO2023056264A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311784A true IL311784A (en) | 2024-05-01 |
Family
ID=84329267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311784A IL311784A (en) | 2021-09-29 | 2022-09-27 | Substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400561A1 (enExample) |
| EP (1) | EP4408843A1 (enExample) |
| JP (1) | JP2024538602A (enExample) |
| KR (1) | KR20240089127A (enExample) |
| CN (1) | CN118251393A (enExample) |
| AU (1) | AU2022356377A1 (enExample) |
| CA (1) | CA3233673A1 (enExample) |
| IL (1) | IL311784A (enExample) |
| MX (1) | MX2024003948A (enExample) |
| WO (1) | WO2023056264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024538602A (ja) * | 2021-09-29 | 2024-10-23 | ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド | インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| TW201910317A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CN111315733A (zh) * | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| JP2024538602A (ja) * | 2021-09-29 | 2024-10-23 | ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド | インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物 |
-
2022
- 2022-09-27 JP JP2024519269A patent/JP2024538602A/ja active Pending
- 2022-09-27 MX MX2024003948A patent/MX2024003948A/es unknown
- 2022-09-27 EP EP22801649.9A patent/EP4408843A1/en active Pending
- 2022-09-27 KR KR1020247014041A patent/KR20240089127A/ko active Pending
- 2022-09-27 AU AU2022356377A patent/AU2022356377A1/en active Pending
- 2022-09-27 CA CA3233673A patent/CA3233673A1/en active Pending
- 2022-09-27 US US18/696,901 patent/US20240400561A1/en active Pending
- 2022-09-27 CN CN202280075492.3A patent/CN118251393A/zh active Pending
- 2022-09-27 IL IL311784A patent/IL311784A/en unknown
- 2022-09-27 WO PCT/US2022/077120 patent/WO2023056264A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240089127A (ko) | 2024-06-20 |
| CA3233673A1 (en) | 2023-04-06 |
| JP2024538602A (ja) | 2024-10-23 |
| US20240400561A1 (en) | 2024-12-05 |
| MX2024003948A (es) | 2024-06-28 |
| EP4408843A1 (en) | 2024-08-07 |
| AU2022356377A1 (en) | 2024-04-11 |
| CN118251393A (zh) | 2024-06-25 |
| WO2023056264A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4173353C0 (en) | CONFIGURATION OF LOW ENERGY POSITIONING MEASUREMENTS | |
| IL280139A (en) | Sulphonylureas as inhibitors of interleukin-1 activity | |
| AR120184A1 (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| EP4069212A4 (en) | INHIBITORS OF HIF-2ALPHA | |
| EP4126179A4 (en) | MOLDED SWAB HEAD | |
| ECSP21090462A (es) | Aril amidinas fungicidas | |
| MA55695A (fr) | Composés chimiques comme inhibiteurs de l'activité interleukine-1 | |
| ATE552255T1 (de) | 4-aminoindazole | |
| EP4508919C0 (en) | CONFIGURATION OF MULTIPLE TIME ADVANCE VALUES | |
| EP4128931A4 (en) | MULTI-MODE CONFIGURATION FOR COVERAGE IMPROVEMENTS | |
| EP4225310A4 (en) | HETEROARYL AMIDE INHIBITORS OF CD38 | |
| EP4333821A4 (en) | SARS-COV-2 INHIBITORS | |
| IL313475A (en) | Use of isoxazolinecarboxamide for sprout inhibition | |
| EP4238974A4 (en) | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | |
| IL281742A (en) | Novel compounds as nadph oxidase inhibitors | |
| EP4305043A4 (en) | Purification of sialooligosaccharides | |
| EP4360641A4 (en) | USE OF MAZDUTIDE | |
| IL310871A (en) | Thiadiazolone derivatives useful as ampk activator | |
| IL285119A (en) | Use of spiropidion | |
| UY37121A (es) | Compuestos de N-(2-(fenil) piridina-4-il)-5-morfolinopiridina-3-sulfonamida como inhibidores de la actividad PL3-quinasa | |
| IL307342A (en) | Formulations of apremilast | |
| EP4271679A4 (en) | AMORPHOUS FORM OF PRETOMANIDES | |
| DK3790529T3 (da) | Formulering omfattende aktivt oxygen | |
| IL315118A (en) | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity | |
| EP4436570A4 (en) | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS |